PE anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
1_145-2c11
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 1_145-2c11
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 2_145-2C11_PE_CD3e_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE (filled histogram) or Armenian hamster IgG PE isotype control (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100307 50 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100308 200 µg 92€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  2. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  3. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  7. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  8. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  9. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  10. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  11. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  12. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  13. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  14. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  15. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  16. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  17. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  18. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  19. Motozono C, et al. 2014. Microbes Infect. 16:320. PubMed
  20. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  21. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  22. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  23. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  24. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  25. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  26. Vazquez S, et al. 2015. Exp Hematol. 43: 578-585. PubMed
  27. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  28. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  29. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  30. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  31. Vitoriano-Souza J, et al. 2012. PLoS One. 7:e40745. PubMed
  32. Zhang B, et al. 2016. Mol Cell. 63: 976-89. PubMed
  33. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  34. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  35. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  36. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  37. Gaudreault N, et al. 2013. Am J Pathol. 2:605. PubMed
  38. He L, et al. 2019. iScience. 0.790972222. PubMed
  39. Ma J, et al. 2016. Proc Natl Acad Sci U S A. 113: 450 - 458. PubMed
  40. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  41. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  42. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  43. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  44. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  45. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  46. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  47. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  48. Boulay A, et al. 2015. J Neurosci. 35:4427. PubMed
  49. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  50. Abe M, et al. 2020. Clin Exp Immunol. 303:199. PubMed
  51. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  52. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  53. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  54. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  55. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  56. Guo Y, et al. 2013. Infect Immun . 81:3923. PubMed
  57. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  58. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  59. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  60. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  61. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  62. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  63. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  64. Martin R, et al. 2014. PLoS One. 9:110609. PubMed
  65. Cecchinato V, et al. 2017. J Immunol. 198(1):184-195. PubMed
  66. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  67. Kristensen LK, et al. 2020. Mol Imaging Biol. 1.625694444. PubMed
  68. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  69. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  70. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  71. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  72. Ji XJ, et al. 2019. Mediators Inflamm. 2019:2750528. PubMed
  73. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  74. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  75. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  76. Hu KH, et al. 2020. Nat Methods. 1.286805556. PubMed
  77. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  78. Celià-Terrassa T, et al. 2017. Nat Cell Biol. 19:711. PubMed
  79. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  80. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  81. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  82. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  83. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  84. Artinger M, et al. 2021. Int J Mol Sci. 22: . PubMed
  85. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  86. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  87. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  88. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  89. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
RRID
AB_312672 (BioLegend Cat. No. 100307)
AB_312673 (BioLegend Cat. No. 100308)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account